光子计数探测器CT在多发性骨髓瘤中的系统评价与试验序贯荟萃分析：图像质量与辐射剂量
该系统评价与荟萃分析纳入5项研究（170例多发性骨髓瘤患者），比较光子计数探测器CT（PCD-CT）与能量积分探测器CT（EID-CT）的图像锐利度和辐射剂量。PCD-CT在图像锐利度上显著改善（平均差+0.99分，95%CI 0.62-1.37，p<0.001），常规荟萃分析提示辐射剂量降低（平均差-4.95 mGy，95%CI -8.39至-1.50，p=0.005），但试验序贯分析认为剂量降低证据尚不充分。
要点
- PCD-CT较EID-CT可显著提升多发性骨髓瘤骨病变的图像锐利度。
- 常规荟萃分析提示PCD-CT降低辐射剂量，但试验序贯分析未达确定性结论。
- 日常阅片可关注PCD-CT对骨病变细节显示的优势，但剂量获益需个体化权衡。
核心结论
- 与EID-CT相比，PCD-CT在多发性骨髓瘤患者中显著改善主观图像锐利度，试验序贯分析证实该证据稳定。
- 常规荟萃分析提示PCD-CT降低辐射剂量，但试验序贯分析表明累积证据尚不充分，需进一步大样本研究确认剂量降低幅度。
研究设计与样本
- 方法学质量采用ROBINS-I评估，证据确定性采用GRADE评估；比较PCD-CT与EID-CT在多发性骨髓瘤骨病变患者中的图像锐利度和辐射剂量（CTDIvol）。
诊断标准与关键数值
- 图像锐利度：PCD-CT vs EID-CT的合并平均差为+0.99分（95%CI 0.62-1.37，p<0.001）。
- 辐射剂量：PCD-CT vs EID-CT的合并平均差为-4.95 mGy（95%CI -8.39至-1.50，p=0.005），但试验序贯分析提示证据不充分。
临床应用与阅片要点
- 在多发性骨髓瘤骨病变的CT检查中，可优先考虑PCD-CT以提升图像锐利度，利于细微骨病变的显示。
- 尽管常规荟萃分析提示PCD-CT降低辐射剂量，但试验序贯分析未确认，临床决策时应结合患者情况和机构条件谨慎权衡。
局限性
- 纳入研究数量较少（5项系统评价，4项荟萃分析），样本量有限（170例患者）。
- 试验序贯分析显示辐射剂量降低的累积证据尚不充分，需更大规模研究验证。
以上解读依据论文摘要（全文未开放获取或许可不允许翻译转载）。
英文原文（摘要）· 点击展开
OBJECTIVES: To systematically review and perform a meta-analysis comparing the effects of PCD-CT versus EID-CT on image quality (sharpness) and radiation dose (CTDIvol) in patients with bone lesions due to multiple myeloma (MM).
METHODS: A comprehensive search of PubMed, Embase, Scopus, and Cochrane Central was conducted from inception to October 2025. Studies comparing PCD-CT and EID-CT in MM patients were included. Methodological quality was assessed using ROBINS-I, and the certainty of evidence was assessed using GRADE.
RESULTS: A total of 41 studies were identified that matched our search criteria. After duplicate removal and screening, five studies (n = 170 patients) were included in the systematic review, with four contributing to the meta-analysis. PCD-CT showed a significant pooled mean difference in image sharpness (mean difference, + 0.99 points; 95% CI, 0.62-1.37; p < 0.001). PCD-CT also demonstrated a reduction in radiation dose (mean difference, -4.95 milligrays; 95% CI, -8.39 to -1.50; p = 0.005). Trial sequential analysis (TSA) confirmed stability of pooled estimates, with conclusive evidence for image sharpness improvement, and suggestive yet incomplete evidence for radiation dose reduction.
CONCLUSION: Compared to EID-CT in MM, PCD-CT significantly improves subjective image sharpness as supported by trial sequential analysis. Conventional meta-analysis suggested a reduction in radiation dose with PCD-CT; however, trial sequential analysis indicated that the cumulative evidence remains inconclusive. Further large-scale studies are suggested to confirm the magnitude of the radiation dose reduction benefit.
引用
- Ohannesian VA, Taneja BC, do Amaral E Castro A, et al. Photon-counting detector computed tomography (PCD-CT) in multiple myeloma: a systematic review and trial sequential meta-analysis on image quality and radiation dose. Skeletal Radiol. 2026. PMID: 42204008. doi:10.1007/s00256-026-05242-y
供执业医师工作参考，不替代临床判断；数值与分级以指南原文为准。